Abstract: A composition for treating diabetes, in particular type 1 diabetes, in a patient/person having a BMI of more than 28, in particular of more than or equal to 30 and/or an HbA1c of more than 7.6%, includes an insulin and an amylin receptor agonist. The composition can be used in a method of treating overweight and/or obesity by supporting a body weight control for at least 15 weeks in a patient having Type 1 diabetes and having a BMI of more than 28 kg/m2 and/or an HbA1c of more than 7.6%, and a method of treating Type 1 diabetes. The amylin receptor agonist may be a short-acting amylin receptor agonist such as pramlintide.

Abstract: A composition, in the form of an aqueous solution, including an insulin in hexameric form and at least one substituted citrate of formula I: in which: R1, R2, R3, identical or different, represent OH or AA, at least one of the R1, R2, R3 is an AA radical, AA is a radical resulting from a natural or synthetic aromatic amino acid comprising at least one phenyl group or indole group, substituted or not substituted, said AA radical having at least one free carboxylic acid function, and the carboxylic acid functions are in the form of a salt of an alkali metal selected from Na+ and K+.

Abstract: A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.

Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, a prandial insulin or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: An injectable aqueous solution, the pH of which is from 6.0 to 8.0, having at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions have, in addition, a gastrointestinal hormone.

Abstract: The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.6 and 7.8, including at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) a hydrophobized anionic polymer. In one embodiment, the compositions according to the invention also include a prandial insulin.

Abstract: Physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, includes at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions include, in addition, a gastrointestinal hormone.

Abstract: A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, including at least: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is from 6.6 to 7.8, comprises at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) an anionic compound bearing carboxylate charges and hydrophobic radicals. The composition may also include a prandial insulin.

Abstract: The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.6 and 7.8, including at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) a hydrophobized anionic polymer. In one embodiment, the compositions according to the invention also include a prandial insulin.

Abstract: A storage-stable pharmaceutical composition includes an aqueous solution of at least an antibody-derived therapeutically active protein chosen amongst antibody, nanobody or fusion protein and an amount effective to stabilize the antibody-derived therapeutically active protein of at least one lauryldimethylamineoxide and/or of one of its amine oxide analogs.

Abstract: A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.

Abstract: A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound.

Abstract: The present invention provides guanidine compounds and salts thereof that may be useful, for example, in the preparation of herbicidal compositions. The compounds may be used, for example, to prepare N-phosphonomethylglycine guanidine salts having improved herbicidal efficacy over glyphosate alone.

Abstract: The invention relates to a composition in aqueous solution, including insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, said saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. The invention also relates to a pharmaceutical formulation comprising a composition as claimed in any one of the preceding claims.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: A composition, in the form of an aqueous solution, including an insulin in hexameric form and at least one substituted citrate of formula I: in which: R1, R2, R3, identical or different, represent OH or AA, at least one of the R1, R2, R3 is an AA radical, AA is a radical resulting from a natural or synthetic aromatic amino acid comprising at least one phenyl group or indole group, substituted or not substituted, said AA radical having at least one free carboxylic acid function, and the carboxylic acid functions are in the form of a salt of an alkali metal selected from Na+ and K+.

Abstract: The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles, and to the applications, especially therapeutic applications, of these formulations. Formulations may include an aqueous colloidal suspension of low viscosity based on micrometric particles of a water-soluble, biodegradable, amphiphilic polymer carrying hydrophobic groups and ionizable hydrophilic groups that are at least partially ionized, said particles being capable of associating spontaneously and non-covalently with an active principle, at pH=7.0, under isotonic conditions. This suspension contains multivalent ions of opposite polarity to that of the hydrophilic groups, the ratio r, defined by the formula r=n×([IM]/[GI]), where n is the valency of said multivalent ions, [IM] is the molar concentration of multivalent ions, [GI] is the molar concentration of ionizable groups GI, being between 0.3 and 10.